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Intensity-Modulated Radiotherapy After Extrapleural
Pneumonectomy in the Combined-Modality Treatment of
Malignant Pleural Mesothelioma
Alexander Chi, MD,* Zhongxing Liao, MD,† Nam P. Nguyen, MD,* Carol Howe, MD,‡
Daniel Gomez, MD,† Si Young Jang, PhD,* and Ritsuko Komaki, MD†
Introduction: Local therapy is becoming increasingly important as
a part of the definitive treatment for malignant pleural mesothelioma
after extrapleural pneumonectomy (EPP) because of the emer-
gence of trimodality therapy consisted of chemotherapy, EPP,
and adjuvant radiotherapy. Herein, we explore the current evi-
dence and indications for adjuvant intensity-modulated radiother-
apy (IMRT), as well as how to further improve this technique and
adapt new technology in the delivering adjuvant radiotherapy in
the setting of trimodality therapy.
Methods: A systematic review of relevant studies identified through
PubMed, ISI Web of Knowledge (Web of Science), the Cochrane
Library, and the National Guideline Clearinghouse search engines
was performed.
Results: Local control remains poor despite the inclusion of
conventional adjuvant radiation therapy in trimodality therapy.
This can be improved by the delivery of adjuvant IMRT. How-
ever, IMRT can be associated with severe pulmonary toxicity if
the radiation dose to the remaining lung is not kept to a very low
level. This is especially true when patients are receiving chemo-
therapy. New advances in technology can allow for lower doses
to the contralateral lung, decreased treatment delivery time, and
improved target dose coverage.
Conclusion: Excellent local control can be achieved through adju-
vant IMRT after EPP for malignant pleural mesothelioma. Severe
pulmonary toxicity may be avoided by setting stringent dose con-
straints for the contralateral lung. This can be aided by the advances
in technology. Post-treatment surveillance may be reliably con-
ducted by periodical [18F]-fluorodeoxyglucose-positron emission
tomography imaging.
Key Words: Malignant pleural mesothelioma, Extrapleural pneu-
monectomy, IMRT.
(J Thorac Oncol. 2011;6: 1132–1141)
Malignant pleural mesothelioma (MPM) is an aggressivebut rare thoracic malignancy that occurs in approxi-
mately 3000 people in the United States annually.1 Its inci-
dence will peak in between 2005 and 2010 and decline
thereafter.2 This is mainly due to restrictions in exposure to
asbestos, which has been strongly associated with the devel-
opment of mesothelioma, and the disease’s latent nature.3 The
development of MPM has also been associated with previous
supradiaphragmatic irradiation, exposures to carbon nano-
tubes, simian virus-40 (SV-40), intrapleural thorium dioxide,
and the inhalation of other fibrous silicates, such as erion-
ite.4–7 However, MPM remains a serious problem with its
incidence rising worldwide.1 The treatment of MPM is very
challenging with median survival (MS) of less than 20
months reported in most series.1 Local therapy is the primary
treatment modality because MPM is known to remain local-
ized in the ipsilateral hemithorax early in its clinical course.
The initial approach is usually surgical resection, such as
pleurectomy and decortication (P/D), or extrapleural pneu-
monectomy (EPP). In general, surgery alone is associated
with high local recurrence rates, with EPP demonstrating
improved local control but higher incidence of distant metas-
tases (DM) compared with P/D.8 As shown by Pass et al.,9
local recurrence was 69% after P/D and 38% after EPP after
a median follow-up of 33.7 months (p  0.05). Despite poor
local control, longer MS was achieved after P/D compared
with that after EPP (14.5 months versus 9.4 months). In
addition, the DM rate was much higher after EPP compared
with that after P/D. Radiotherapy (RT) alone is not the
treatment of choice for this disease because of the inability to
deliver a therapeutic dose of radiation (approximately 60 Gy
in 30 fractions) to the pleura without overdosing the ipsilat-
eral lung parenchyma and causing severe pulmonary toxic-
ity.10 Because of the high local recurrence rate after sur-
gery and the radiosensitivity of lung tissue, adjuvant RT
has been attempted after P/D or EPP. Without significant
improvement in local control after P/D, RT has been
shown to decrease local recurrence after EPP.11–14
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With the significantly improved response rate, pro-
gression-free survival, and overall survival (OS) associ-
ated with the cisplatin/pemetrexed doublet regimen in
unresectable MPM over cisplatin alone, trimodality ther-
apy (neoadjuvant or adjuvant doublet chemotherapy, EPP,
and adjuvant RT) has emerged to become the most com-
mon treatment approach for resectable MPM.13–29 After
trimodality therapy, improved MS of more than 20 months
is demonstrated in selected studies, supporting such treat-
ment approach.14,16–18,20,21,23–25
As the treatment for MPM advances, technology has
also progressed to allow further refinements in radiation
therapy planning and delivery to enhance locoregional con-
trol while minimizing radiation toxicity through intensity-
modulated RT (IMRT).30 In a study by Rice et al., only 5%
local recurrence within the irradiated field and 13% locore-
gional recurrence were observed in patients treated with EPP
and adjuvant IMRT.31 In this study, most patients had an
excellent toxicity profile after IMRT. There was only one
death due to the development of bronchopleural fistula after
32 Gy was delivered. However, a 46% incidence of fatal
pneumonitis was reported when stringent dose constraints for
the remaining lung were not set during IMRT treatment
planning.32 Therefore, the technical aspects of IMRT treat-
ment planning and delivery are of pertinent importance in
achieving high locoregional control with minimal adverse
effects after radical surgical resection for MPM.
In this review, we discuss why adjuvant IMRT is
clinically indicated in the setting of trimodality therapy con-
sisted of chemotherapy, EPP, and radiation therapy; the
known adverse effects of IMRT; and how to best avoid severe
toxicities in the planning of IMRT for MPM. Furthermore,
we summarize the adaptation of new technology in recent
years and the post-treatment imaging surveillance of MPM
with [18F]-fluorodeoxyglucose (FDG)-positron emission to-
mography (PET).
METHODS
Literature Search Strategy
Electronic searches were performed in the following
databases: PubMed, ISI Web of Knowledge (Web of Sci-
ence), the Cochrane Library, and the National Guideline
Clearinghouse. In PubMed, the term “Mesothelioma” was
searched as both keyword and Medical Subject Headings
(MeSH) term, and the results were combined with searches
for the MeSH terms “Radiotherapy, Intensity-Modulated”
and “Extrapleural pneumonectomy” and key phrases “Inten-
sity-Modulated Radiotherapy,” “Intensity-modulated radia-
tion,” “IMRT,” “FDG-PET,” and “PET/CT.” In addition, a
separate search was done for the MeSH term “Radiotherapy,
Intensity-Modulated/adverse effects.” All “Related Citations”
for results found in PubMed were searched as well.
Web of Science, the Cochrane Library, and National
Guideline Clearinghouse were searched using the keywords
noted earlier. All identified article titles were then entered
into Web of Knowledge individually, resulting in a list of
articles citing the originally identified articles. This list was
then culled for inclusion in the set of articles to be reviewed.
Selection Criteria
Eligible studies for the present review included those in
which patients with histologically proven MPM were treated
with EPP and adjuvant RT with or without neoadjuvant/
adjuvant chemotherapy. For studies that included patients
who underwent EPP as a subset of patients who had other
treatments, results for patients who underwent EPP were
extracted when possible. Only the most complete and most
recent reports of duplicated studies were included for quali-
tative appraisal. All publications were limited to human
subjects and English language. Physics studies that were
describing IMRT techniques only were included as well.
Abstracts, case reports, conference presentations, editorials,
and expert opinions were excluded.
Data Extraction and Critical Appraisal
The findings from the initial searches were used to
decide the clinical outcome for the present review. The
primary outcome was assessed by local and locoregional
failure after EPP and adjuvant RT with or without chemo-
therapy. The secondary outcomes were the incidence of DM
and median OS; the incidence of severe pulmonary toxicity
after adjuvant IMRT; and the sensitivity, specificity, and
positive and negative predictive values (NPV) of FDG-PET
and PET/computed tomography (CT) for recurrent MPM.
RESULTS
Quantity of Trials
A total of 81 references were identified through the four
electronic database searches after exclusion of duplicate or
irrelevant references. After applying the selection criteria,
only 60 remained for assessment. Among them, 15 studies
were found reporting the clinical outcome of trimodality
therapy, and 7 studies were found reporting the clinical
outcome and toxicity of adjuvant IMRT after EPP. In addi-
tion, 12 studies were found which were to explore the physics
and technical aspects of adjuvant IMRT after EPP.
Clinical Outcome After Multimodality
Treatment Consisted of EPP and Adjuvant
Radiation Therapy with or without
Chemotherapy
In a phase II study from Memorial Sloan Kettering
Cancer Center, adjuvant hemithoracic RT to 54 Gy with
conventional fractionation was shown to improve the local
control of MPM after EPP, with only a few local recurrences
at the margin of the radiation field.13 In this study, radiation
was well tolerated with only one case of grade 4 esophago-
pleural fistula. However, higher local recurrence rates have
been observed after adjuvant RT (mostly conventional RT
with some including IMRT in a small portion of patients)
with or without chemotherapy in other studies (Table
1).14,16,18,20,33 A MS of 17 months was achieved in the study
by Rusch et al.13 In general, trimodality therapy has been
frequently associated with MS of approximately 20 months or
more with acceptable toxicity profile when the patients were
treated with conventional RT (Table 1).
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Local recurrence continues to be a major challenge in
the treatment of MPM even after adjuvant RT. In a study by
Gupta et al., crude locoregional recurrence of 41% has been
reported after a median follow-up of 17 months when 78
patients (mostly stage II–III) were treated with high-dose
hemithoracic radiation of 50 Gy after EPP.33 Furthermore,
the authors suggested that two of three of these patients who
failed locally may recurr in areas that could possibly be
underdosed. This can happen with conventional RT because
the concave shape of the target volume being treated, the size
of the target volume, and the number of adjacent critical
structures make it difficult to achieve a therapeutic dose
homogeneously covering the entire target volume.
Underdosage due to dose inhomogeneity can possibly
be avoided by intensity modulation, which conforms a high
dose to the target volume while sparing adjuvant normal
structures, such as the heart, spinal cord, esophagus, con-
tralateral lung, and liver.30 Figure 1 demonstrates a regular
IMRT treatment plan with the prescription dose of 45 Gy well
conformed to the ipsilateral hemithorax. Since the initial
report of this technique, only 13% locoregional recurrence
was observed with 5% in-field recurrence among 63 mostly
stage III–IV patients treated with adjuvant IMRT (median
dose of 45 Gy to the hemithorax) after EPP at M. D.
Anderson Cancer Center.31 The MS in these patients was 14.2
months, and the 3-year OS was 20%. However, the DM rate
was 54%, with only seven patients receiving chemotherapy
(six neoadjuvant and one adjuvant). The excellent local
control after adjuvant IMRT was corroborated in a study by
van Sandick et al., which demonstrated only 9% local failure
after a median follow-up of 17 months.34 Furthermore, IMRT
was shown to be associated with a lower incidence of local
recurrence when compared with conventional RT after neo-
adjuvant chemotherapy and EPP.24 In this study, the local
recurrence was significantly lower after adjuvant IMRT com-
pared with conventional RT after a median follow-up of 20.6
months in patients who underwent EPP (14.3% versus 41.7%,
p  0.03). Although high local recurrence has been reported
in one study after IMRT, this is inconclusive and difficult to
interpret because of the small number of patients presented.35
Toxicity from Adjuvant IMRT After EPP
Despite the excellent local control reported in selected
studies, adjuvant IMRT for MPM has also been associated
with severe pulmonary toxicity (Table 2). In the study by
Rice et al., six pulmonary-related deaths (PRDs) have been
reported after IMRT to a median dose of 45 Gy with con-
ventional fractionation, while one patient who has a small
bronchopulmonary fistula suffered from severe respiratory
distress during radiation and later died of sepsis.31,36 On
further analysis, PRDs were related to higher percentages of
the contralateral lung volume receiving 20 Gy (V20), 10
Gy (V10), the mean lung dose (MLD), as well as the absolute
contralateral lung volume (ml) receiving 5 and 10 Gy. How-
ever, V20 was the only significant factor on multivariate
analysis. All six PRDs had high percentage of the remaining
lung receiving 5 Gy (V5). Among them, the V5 was more
than 80% in all but one case, which was 63%. The MLD was
high as well (8.5 Gy except one at 8.1 Gy), which can alsoTA
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be correlated with severe pulmonary toxicity potentially.
More severe pulmonary toxicity has been reported when
chemotherapy was given as part of a trimodality regimen, and
strict dose constraints were not followed.32,35,37 In a study by
Allen et al., 13 patients underwent two to six cycles of
cisplatin and pemetrexed, EPP, and adjuvant IMRT to 54 Gy
in 30 fractions.32 Among them, six (46%) developed grade 5
radiation penumonitis (RP) with a median onset of 30 days
from the completion of IMRT. The dose constraints used are
listed in Table 2. In the patients who developed severe RP,
the MLD, V5, and V20 were more than 13 Gy, 80%, and 15%
in all cases. With similar dose constraints, four grade 5 RP
were reported after trimodality therapy in 13 patients by
Kristensen et al.37 In the patients who suffered grade 5 RP,
the MLD, V5, V10, and V20 were more than 13 Gy, 90%,
55%, and 8% in all cases. In all these three studies, high
incidence of severe RP was encountered when MLD and V5
were higher than 8.5 Gy and 80%, respectively, especially
when chemotherapy was given. This commonality further
supports the setting of stringent MLD and V5 constraints in
the planning of adjuvant IMRT. Less severe pulmonary
toxicity was encountered when more strict dose constraints
were set for the contralateral lung as shown by Miles et al.35
In this study, only one fatal pulmonary death was encoun-
tered 6 months after adjuvant IMRT as part of trimodality
therapy. Again, high MLD and V5 compared with the median
of those without FPT (11.4 versus 7.6 Gy and 92% versus
66%) were observed in this patient. In another study from the
University of Pennslyvania, no fatal toxicity was encountered
despite high MLD of10 Gy and high V5 of80% for most
patients. However, the majority of patients in this study did
not receive chemotherapy. One fatal pulmonary toxicity after
adjuvant IMRT was also reported in a phase II prospective
study by Krug et al.21 Therefore, the majority of the studies
suggest that MLD, V5, and V20 will all need to be kept fairly
low for the contralateral lung, especially when chemotherapy
is given in the setting of trimodality therapy, to avoid severe
pulmonary toxicity.
Techniques of Adjuvant IMRT Treatment
Planning and Delivery
Because of the high incidence of fatal pulmonary tox-
icity encountered initially, ways of refining existing ap-
proaches of treatment planning have been sought by Allen et
al.32,39 Other than limiting the MLD to 9.5 Gy, V20 to
10%, and V5 to 60%, the authors further restricted the
spacing of IMRT beams as they enter the patient’s body
contour. The contrlateral lung is much more likely to be
spared with such an approach. To further decrease the chance
of entering radiation beams from entering the contralateral
lung, the superior portion of the planning target volume
(PTV) was treated with only three to four beams, which did
not pass through the contralateral lung parenchyma. The
sparing of normal critical structures and dose homogeneity is
also improved by using nine IMRT beams. Such changes in
the treatment planning of adjuvant IMRT has lead to much
lower V5, V20, and MLD (median 50.8%, 3%, and 6.6 Gy) for
the contralateral lung compared with their initial report.
The initial treatment planning was very labor-intensive
and required a significant amount of time for plan optimiza-
tion. This is mainly due to the very large target volume
treated and the need to spare multiple critical organs adjacent
to it. However, treatment efficiency is much improved with
more recent planning systems, such as Pinnacle or Eclipse,
and the avoidance of using multileaf collimators with narrow
leaf width.40,41 Because of the severe pulmonary toxicity
associated with high MLD and V5 as described earlier, it is of
pertinent importance to have an accurate measurement of
volumes receiving low doses. Dose underestimation in the
low-dose regions can occur and has been reported when
adjuvant IMRT is planned with commercial treatment plan-
ning systems, such as Pinnacle and Corvus systems. In fact,
underestimation of dose 10 Gy can be up to 25% in
mesothelioma patients planned for adjuvant IMRT with the
Pinnacle system.42 This is mainly due to the dose scattering
from the multileaf collimators. Thus, a Monte-Carlo planning
FIGURE 1. Axial, sagittal, and coronal images of a regular intensity-modulated radiotherapy treatment plan for malignant
pleural mesothelioma after extrapleural pneumonectomy. The absolute dose levels in centigray (cGy) are listed on the upper
left of each image from 500.0 to 6600.0 cGy, which equals to 5–66 Gy. The prescription dose of 45 Gy is well confined to
the ipsilateral hemithorax (blue line) with the sparing of the heart and the spinal cord. Significant amount of the right lung is
also spared of low dose (5 Gy) spread from the treated volume (light purple line).
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algorithm-based system, which provides the most sophisti-
cated and accurate dose calculation algorithms developed for
IMRT, should be used to confirm the dose distribution in the
low-dose regions in the planning of adjuvant IMRT for MPM
if possible. Alternatively, more stringent V5 for the contralat-
eral lung can be set in the optimization of adjuvant IMRT to
account for this dose underestimation. However, this underesti-
mation of dose parameters for the contralateral lung is less
pronounced with the superposition convolution algorithm com-
pared with the pencil-beam algorithm of dose calculation.43
Technical Advances
The technical aspects of adjuvant IMRT after EPP for
MPM can be further improved with recent advances in
technology. One such example is the use of helical tomo-
therapy (HT) in the delivery of image-guided IMRT for
MPM. HT is a technology that delivers fan-beam IMRT
under daily megavoltage CT image guidance.44 This is com-
pleted through continuous and synchronous gantry rotation
and couch movement during radiation delivery. The unique
advantage of HT is its ability to provide intensity modulation
through 51 separate angles per gantry rotation, thus generat-
ing highly conformal dose avoidance of critical structures,
which achieved excellent dose homogeneity in the target
volume. HT has been shown to improve dose homogeneity
and decrease dose to the normal critical structures for various
sites when compared with linac-based IMRT.45,46 When com-
pared with step-and-shoot IMRT in the delivery of adjuvant
IMRT for MPM, HT was found to have statistically signifi-
cant improvement in target volume coverage, homogeneity
index, and lower average V5 of 40% and MLD of 5 Gy,
which can potentially lead to superior local control and lower
incidence of fatal pulmonary toxicity compared with those
reported in the literature.47 In addition, HT treatment delivery
time is found to be similar to that for step-and-shoot IMRT.
Figure 2 demonstrates the treatment plan for a patient with
HT who was treated at the University of Arizona. As shown
in this case, HT can achieve excellent contralateral lung
sparing (V5 of only 30.2%) and dose coverage of the ipsilat-
eral hemithorax after EPP.
Another form of intensity-modulated arc therapy, such
as RapidArc, which is delivered through the regular linear
accelerator, has also demonstrated superior V20 for the con-
tralateral lung and improved clinical target volume coverage
in addition to shorter treatment delivery time than regular
linac-based IMRT.48 To further decrease radiation dose to the
contralateral lung, proton therapy has been compared with
intensity-modulated photon therapy.49 Protons are heavy par-
ticles with a charge of 1. Their penetration of in matter is
finite because of their mass. As a result, the dose immediately
beyond the distance that proton travels in the tissue is virtu-
ally zero.50 This unique physical property distinguishes pro-
ton from photon beams, which are electromagnetic waves
losing their energy exponentially with depth in an absorber
because of their lack of mass and charge. Thus, modulated
proton beams can significantly decrease the dose to critical
organs adjacent to the target volume. In addition to normal
tissue sparing, this also allows for further dose escalation to
improve target volume dose coverge. Through the uniqueTA
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beam characteristics of proton therapy, significantly superior
PTV coverage and lower V5, V15, and V20 of the contralateral
lung (2%) can be achieved.49
Surveillance After Adjuvant IMRT
FDG-PET/CT has emerged to be a major tool used in
the diagnosis of MPM because of its high sensitivity and the
difficulty in the application of CT criteria of tumor response
after treatments for MPM.51,52 Furthermore, PET has been
reported to have sensitivity, specificity, and accuracy of more
than 90% in the diagnosis of MPM.53 In addition, MPM has
been associated with significantly higher mean standard up-
take value when compared with that associated with benign
pleural disease. The prognostic value of PET has been shown
in various studies.52 More recently, early metabolic response
after two cycles of pemetrexed-based palliative chemother-
apy per FDG-PET has been shown to predict for longer time
to tumor progression in a small study by Ceresoli et al.54
Similar findings were found after chemotherapy in other
retrospective studies as well.52 The predictive value of
PET/CT for MPM after trimodality therapy is further sup-
ported in a study of 25 patients by Tan et al.55 In this study,
all patients were treated with chemotherapy, EPP or P/D, and
RT. Each patient was scanned at a minimum of 3 months
after RT. PET/CT had a sensitivity of 94%, specificity of
100%, positive predictive value of 100%, and NPV of 88% in
the detection of recurrent disease. Thus, the predictive value
of PET/CT after trimodality therapy warrants further evalu-
ation in a prospective study.
DISCUSSION
The treatment of MPM has traditionally been palli-
ative in the past with poor survival outcome of less than 12
months.56 However, the multimodality approach of EPP,
adjuvant RT, and systemic chemotherapy has quickly
emerged as the standard treatment approach for MPM due
to the improved survival seen with cisplatin and pem-
etrexed over cisplatin alone, the constant technical refine-
ment in EPP, and decreased local recurrence after adjuvant
hemithoracic RT.13,15,17 A MS of 21 months has been
reported in 120 patients treated in this approach by Sug-
arbaker et al.17 Improved MS of more than 20 months after
trimodality therapy was frequently observed in various
studies.14,16–18,20,21,23–25 However, local control continues
to be a problem despite this improvement in survival. In
fact, local failure of more than 30% has been frequently
found after trimodality therapy, which delivered adjuvant
RT with conventional techniques (Table 1).
IMRT is an approach to deliver a desired dose of
radiation highly conformed to a concave-shaped target, such
as the hemithorax, to avoid underdosing the PTV and over-
dosing the surrounding critical structures, such as the spinal
cord, esophagus, major vessels, the heart, and the contralat-
eral lung. The adaptation of this technology in the delivery of
adjuvant RT for MPM has been well described in the
past.30,57 In the largest study to date, there was only 13%
locoregional failure (5% local failure in the irradiated field
and 5% marginal misses) after IMRT.31 The MS was only 14
months, with most patients not receiving chemotherapy. In-
trapleural cisplan followed by EPP and adjuvant IMRT has
been causing high mortality due to sever pneumonitis in the
remaining lung.58,32
Epitheliod histology and pN0 status were both found to
be significant predictors for longer survival in this study.
When compared with conventional RT in the setting of
trimodality therapy, adjuvant IMRT was found to signifi-
cantly improve local control as described by Buduhan et al.24
FIGURE 2. These are the axial, coronal, and sagittal views of a treatment plan to deliver image-guided intensity-modulated
radiotherapy through helical tomotherapy (HT) to treat a patient with malignant pleural mesothelioma of the left pleura, epi-
thelioid type, pathological T4N2M0, stage IV after induction chemotherapy consisted of cisplatin and pemetrexed, and extra-
pleural pneumonectomy. The dose levels are represented by shades in different colors. The dose that each color represents is
listed on the right side. The entire ipsilateral hemithorax was treated to 45 Gy in 25 fractions, which covered 99.2% of the
planning target volume (PTV1), encompassing the entire hemithorax with margin. The area of high risk for microscopic resid-
ual disease was boosted to 60 Gy. This dose was delivered in a simultaneously integrated fashion in 25 fractions as well. The
boost volume (red volume at the posterior-inferior left hemithorax as shown in the saggital view) was well covered by the
95% isodose (57 Gy) volume. The V5, V20, and MLD of the remaining lung were 30.2%, 5.2%, and 6.1 Gy, respectively.
The patient had no acute or late pulmonary toxicity.
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In prospective phase II studies, local control also seemed to
be improved when IMRT was allowed. In a phase II multi-
center trial by Krug et al.,21 40 patients with stage I–III MPM
underwent four cycles of cisplatin and pemetrexed, EPP, and
adjuvant RT to 54 Gy in 30 fractions. Crude local failure rate
after EPP was 20.4%, while the MS was 29.1 months. In
another phase II study from the European Organisation for
Research and Treatment of Cancer Lung Cancer Group, 37
patients underwent trimodality therapy consisted of three
cycles of neoadjuvant cisplatin/pemetrexed, EPP, and adju-
vant RT to 54 Gy in 30 fractions.23 In this study, 14 of 38
patients who received adjuvant RT underwent IMRT. The
locoregional recurrence was only 16.2% after a median fol-
low-up of 19.3 months, whereas the MS was 33 months in
these patients who received trimodality therapy.
Severe pulmonary toxicity after IMRT has been re-
ported by several groups as shown in Table 2. Despite the
small number of patients involved, high incidence of grade 5
pulmonary toxicity is frequently observed when the MLD and
V5, V10, and V20 for the contralateral lung was high, espe-
cially when chemotherapy was administered.32,35–37 This im-
plies the importance of keeping these dosimetric parameters
for the contralateral lung to a low level. Because of the rarity
of this aggressive disease, it may be difficult to obtain a
threshold for each parameter. However, patients who suffered
severe pulmonary toxicity had MLD 8.5 Gy, V5 80%,
V10 55%, and V20 7% in general in the studies presented.
Thus, it may be prudent to keep the four parameters to below
these levels. Furthermore, one needs to take the underestima-
tion of radiation dose 10 Gy into consideration during the
treatment planning with the current planning systems.42
Therefore, the V5 may need to be lowered further to be kept
less than 60% instead of 80%. To further decrease radiation
dose to the contralateral lung, limiting the angle of photon
beams entering the patients body on the ipsilateral side and
avoiding the exiting of radiation beams through the contralat-
eral lung were also attempted with success.39 Many investi-
gators have sought to decrease radiation dose to the critical
normal structures by combining electron and three-dimen-
sional conformal photon therapy. Radiation dose to the con-
tralateral lung may be decreased with this approach when
compared to IMRT without significantly underdosing the
PTV.59 However, this approach was also found to be associ-
ated with poorer PTV coverage dosimetrically and high
incidence of locoregional failure clinically.33,60 Others have
sought to combine electron therapy and IMRT, which has
demonstrated improved sparing of critical structures other
than the contralateral lung.61 Clinical outcome from this
approach is awaited.
Refinement in the delivery of IMRT as well as the
adaptation of new technology may further improve the safety
and efficacy of adjuvant RT in providing excellent local
control for MPM after EPP. Despite limited investigation in
this area, HT was shown to further decrease the MLD and V5
of the contralateral lung to less than 5 Gy and 40%, respec-
tively.47 HT is consisted of a 6-MVlinear accelerator mounted
on the gantry of a helical CT scanner.44 HT is able to
modulate radiation intensity through 51 independent angles
over one gantry rotation while the patient is moving synchro-
nously and continuously through the gantry bore. Because of
this, it is able to generate highly conformal IMRT plans
delivered under megavoltage CT image guidance. However,
HT is not as widely available as the regular linear accelerators
throughout the world. Therefore, other approaches of deliv-
ering intensity-modulated volumetric arc therapy have been
sought. Recently, a new method of delivering volumetric
intensity modulated arc therapy, the RapidArc, has been
adopted by many clinics. This linac-based approach is shown
to markedly decrease treatment delivery time compared with
regular IMRT.48 The clinical outcome for such technology is
still awaited. However, such advances may lead to further
improvement in clinical outcome in the future. At last, proton
beam therapy has been slowly maturing over the years, which
may also make significant strive to further decrease radiation
dose to the critical thoracic structures at risk. This is due to
proton beam’s finite range in tissue and the fact it deposits
most of its energy at a specific energy-dependent depth
(Bragg peak). This lowers the dose exiting through the
contralateral lung tremendously compared with photon IMRT.49
The physical property of proton beam can potentially lead to
both decreased dose to the organs at risk and improved dose
coverage of a very large target volume, such as in MPM after
EPP, through further dose escalation. More clinical investiga-
tions in this area are eagerly awaited at this time.
FDG-PET has been shown to be fairly sensitive, spe-
cific, and accurate in the diagnosis of MPM in small studies.51
It has also been shown to be associated with treatment
outcome in various studies.52–55 PET/CT is increasingly being
used for surveillance after trimodality therapy as it emerges to
become the standard definitive treatment in the management
of MPM. Despite the high sensitivity, specificity, positive
predictive value, and NPV found in small studies, PET/CT
value still needs to be further confirmed in prospective
clinical trials. Furthermore, many questions regarding to the
use of PET/CT are still left unanswered. These include when
to have the patients undergo their first PET/CT after adjuvant
IMRT, the frequency and duration of PET/CT imaging, and
the specific definition of recurrence on a PET scan based on
the standard uptake values.
CONCLUSION
MPM is a very aggressive thoracic malignancy, and its
treatment consisting of chemotherapy, EPP, and adjuvant
radiation has given the best survival outcome thus far. Further
improvement in local control of this disease can be achieved
through adjuvant IMRT. However, strict radiation dose con-
straints for the contralateral lung need to be carefully fol-
lowed in the planning of IMRT. On the basis of the reported
clinical outcome after trimodality therapy and dose parame-
ters associated with severe pulmonary toxicity in the current
literature, we propose multimodality therapy with a set of
dosimetric constraints as shown in Figure 3 as a guideline in
the planning of adjuvant IMRT. The advantage of new
technology, such as HT, volumetric modulated arc therapy
(VMAT), and proton therapy in the treatment of MPM after
EPP, and the value of FDG-PET in post-treatment surveil-
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lance need to be further investigated in future prospective
studies.
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